Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index

This retrospective analysis of data from the BIG 2-98 trial (n=2,887) found increasing BMI category was associated with reduced disease-free and overall survival in patients treated with docetaxel-containing chemotherapy. These results need to be confirmed in further studies.


Journal of Clinical Oncology